BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17975155)

  • 1. An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer.
    Plymate SR; Haugk K; Coleman I; Woodke L; Vessella R; Nelson P; Montgomery RB; Ludwig DL; Wu JD
    Clin Cancer Res; 2007 Nov; 13(21):6429-39. PubMed ID: 17975155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
    Wu JD; Odman A; Higgins LM; Haugk K; Vessella R; Ludwig DL; Plymate SR
    Clin Cancer Res; 2005 Apr; 11(8):3065-74. PubMed ID: 15837762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors.
    Wu JD; Haugk K; Coleman I; Woodke L; Vessella R; Nelson P; Montgomery RB; Ludwig DL; Plymate SR
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6153-60. PubMed ID: 17062692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors.
    Plymate SR; Tennant MK; Culp SH; Woodke L; Marcelli M; Colman I; Nelson PS; Carroll JM; Roberts CT; Ware JL
    Prostate; 2004 Nov; 61(3):276-90. PubMed ID: 15368471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.
    Miyake H; Pollak M; Gleave ME
    Cancer Res; 2000 Jun; 60(11):3058-64. PubMed ID: 10850457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of IGF signaling and the androgen receptor in prostate cancer progression.
    Wu JD; Haugk K; Woodke L; Nelson P; Coleman I; Plymate SR
    J Cell Biochem; 2006 Oct; 99(2):392-401. PubMed ID: 16639715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
    Arnold JT; Le H; McFann KK; Blackman MR
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells.
    Schayek H; Seti H; Greenberg NM; Sun S; Werner H; Plymate SR
    Mol Cell Endocrinol; 2010 Jul; 323(2):239-45. PubMed ID: 20417685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
    Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes.
    Gregory CW; Hamil KG; Kim D; Hall SH; Pretlow TG; Mohler JL; French FS
    Cancer Res; 1998 Dec; 58(24):5718-24. PubMed ID: 9865729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft.
    Gregory CW; Kim D; Ye P; D'Ercole AJ; Pretlow TG; Mohler JL; French FS
    Endocrinology; 1999 May; 140(5):2372-81. PubMed ID: 10218991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors.
    Goya M; Miyamoto S; Nagai K; Ohki Y; Nakamura K; Shitara K; Maeda H; Sangai T; Kodama K; Endoh Y; Ishii G; Hasebe T; Yonou H; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2004 Sep; 64(17):6252-8. PubMed ID: 15342412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profile of androgen-independent prostate cancer xenograft LuCaP 23.1.
    Fina F; Muracciole X; Rocchi P; Nanni-Métellus I; Delfino C; Daniel L; Dussert C; Ouafik L'; Martin PM
    J Steroid Biochem Mol Biol; 2005 Sep; 96(5):355-65. PubMed ID: 16043352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interrogating androgen receptor function in recurrent prostate cancer.
    Zhang L; Johnson M; Le KH; Sato M; Ilagan R; Iyer M; Gambhir SS; Wu L; Carey M
    Cancer Res; 2003 Aug; 63(15):4552-60. PubMed ID: 12907631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).
    Nickerson T; Chang F; Lorimer D; Smeekens SP; Sawyers CL; Pollak M
    Cancer Res; 2001 Aug; 61(16):6276-80. PubMed ID: 11507082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
    Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.
    Fahrenholtz CD; Beltran PJ; Burnstein KL
    Mol Cancer Ther; 2013 Apr; 12(4):394-404. PubMed ID: 23348048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
    Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.